Werewolf Therapeutics (HOWL) Current Assets (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Current Assets of $22.9 million for Q2 2026, down 71.54% year-over-year from $80.4 million in Q2 2025, and down 53.03% on a QoQ basis from $48.7 million in Q1 2026.
Werewolf Therapeutics (HOWL) Current Assets (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Current Assets for 7 years, with the latest figure at $22.9 million in Q2 2026.
- Current Assets for Q2 2026 came in at $22.9 million, down 71.54% year-over-year; the trailing twelve-month figure through Jun 2026 was $22.9 million (down 71.54% YoY), and the FY2025 annual result was $58.6 million, down 48.18% from the prior year.
- Current Assets fell to $22.9 million in Q2 2026, from $48.7 million in the prior quarter.
- Over five years, Current Assets peaked at $156.6 million in Q1 2023 and troughed at $22.9 million in Q2 2026.
- A 5-year average of $114.8 million and a median of $138.6 million in 2023 frame the typical range for Current Assets.
- The widest annual swing landed in 2022, when Current Assets jumped 71.37%; it then sank 71.54% in 2026.
- A 5-year view of Current Assets shows it stood at $140.2 million in 2022, then slipped by 1.31% to $138.4 million in 2023, then declined by 18.29% to $113.1 million in 2024, then tumbled by 48.18% to $58.6 million in 2025, then plunged by 60.93% to $22.9 million in 2026.
- Per Business Quant data, the three most recent Current Assets figures were $22.9 million in Q2 2026, $48.7 million in Q1 2026, and $58.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 1.76 Bn |
| 10 | Werewolf Therapeutics | 44.27 Mn | 44.27 Mn | - | 22.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.89 Mn |
| Mar 31, 2026 | 48.73 Mn |
| Dec 31, 2025 | 58.59 Mn |
| Sep 30, 2025 | 68.17 Mn |
| Jun 30, 2025 | 80.44 Mn |
| Mar 31, 2025 | 94.46 Mn |
| Dec 31, 2024 | 113.07 Mn |
| Sep 30, 2024 | 125.84 Mn |
| Jun 30, 2024 | 138.79 Mn |
| Mar 31, 2024 | 142.28 Mn |
| Dec 31, 2023 | 138.37 Mn |
| Sep 30, 2023 | 139.26 Mn |
| Jun 30, 2023 | 147.40 Mn |
| Mar 31, 2023 | 156.56 Mn |
| Dec 31, 2022 | 140.20 Mn |
| Sep 30, 2022 | 151.59 Mn |
| Jun 30, 2022 | 154.17 Mn |
| Mar 31, 2022 | 145.44 Mn |
| Dec 31, 2021 | 161.07 Mn |
| Sep 30, 2021 | 174.40 Mn |